微生态制剂联合传统药物治疗溃疡性结肠炎的评价
Evaluation of Microecologics Combined with Conventional Drugs in the Treatment of Ulcerative Colitis
DOI: 10.12677/md.2026.165063, PDF,   
作者: 周 洋, 王 鑫, 王唯一, 张梦娇, 王天琪：华北理工大学临床医学院，河北 唐山；华北理工大学附属医院消化内科，河北 唐山；张秀静：华北理工大学附属医院消化内科，河北 唐山
关键词: 微生态制剂；溃疡性结肠炎；传统药物；联合治疗；肠道微生态；Microecologics； Ulcerative Colitis； Conventional Medication； Combination Therapy； Intestinal Microecology
摘要: 溃疡性结肠炎(Ulcerative Colitis, UC)是一种慢性非特异性肠道炎症性疾病，其治疗理念正从单纯抑制炎症转向重塑肠道稳态。尽管传统药物在控制症状方面取得了明显进展，但临床应答率有限、复发率高以及长期安全性问题仍是突出的临床瓶颈。肠道微生态失衡不仅是UC发病的核心驱动因素，亦是影响药物疗效的重要变量。随着对“菌群–免疫–代谢”轴认识的深化，微生态制剂与传统药物的联合应用已从辅助支持发展为具有明确协同增效机制的治疗新策略。文章系统梳理该联合疗法的临床证据与分子机制，以期为优化UC个体化治疗提供理论依据与实践指导。
Abstract: Ulcerative colitis (UC) is a chronic nonspecific inflammatory bowel disease, and its treatment concept is shifting from simply suppressing inflammation to remodeling intestinal homeostasis. Although conventional medications have made notable progress in symptom control, limited clinical response rates, high recurrence rates, and long-term safety issues remain prominent clinical bottlenecks. Intestinal dysbiosis is not only a core driver of UC pathogenesis but also an important variable affecting drug efficacy. With a deeper understanding of the “microbiota-immune-metabolism” axis, the combined application of microecologics and conventional drugs has evolved from adjunctive support into a novel therapeutic strategy with clearly defined synergistic mechanisms. This article systematically reviews the clinical evidence and molecular mechanisms of this combination therapy, aiming to provide a theoretical basis and practical guidance for optimizing individualized treatment of UC.
文章引用：周洋, 王鑫, 王唯一, 张梦娇, 王天琪, 张秀静. 微生态制剂联合传统药物治疗溃疡性结肠炎的评价[J]. 医学诊断, 2026, 16(5): 480-489. https://doi.org/10.12677/md.2026.165063

参考文献

[1] 贾玲燕, 柳华, 徐琦德, 等. 肠道微生物群及产物在炎症性肠病中的调节和辅助治疗研究进展[J]. 胃肠病学和肝病学杂志, 2025, 34(9): 1355-1360.
[2] 黄秋玲, 何秋月, 杜艳. 肠道菌群及其代谢物与溃疡性结肠炎的研究进展[J]. 胃肠病学, 2024, 29(4): 248-253.
[3] 苏海水, 方松林, 蔡加锭, 等. 布拉氏酵母菌胶囊联合美沙拉秦肠溶片治疗溃疡性结肠炎患者的临床研究[J]. 中国临床药理学杂志, 2024, 40(24): 3548-3552.
[4] 孙莉莉, 薛青. 粪微生态移植联合柳氮磺吡啶对溃疡性结肠炎患者血清炎症因子及T细胞亚群的影响[J]. 临床输血与检验, 2021, 23(4): 497-501.
[5] 陈迎春, 陈明, 李艺琳. 肠炎宁颗粒联合美沙拉嗪对溃疡性结肠炎患者肠道菌群、炎症因子和UCEIS的影响[J]. 中南医学科学杂志, 2024, 52(3): 460-462.
[6] Huang, L., Zheng, J., Sun, G., Yang, H., Sun, X., Yao, X., et al. (2022) 5-Aminosalicylic Acid Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice by Modulating Gut Microbiota and Bile Acid Metabolism. Cellular and Molecular Life Sciences, 79, Article No. 460.
https://doi.org/10.1007/s00018-022-04471-3
[7] Sandborn, W.J., Vermeire, S., Peyrin-Biroulet, L., Dubinsky, M.C., Panes, J., Yarur, A., et al. (2023) Etrasimod as Induction and Maintenance Therapy for Ulcerative Colitis (ELEVATE): Two Randomised, Double-Blind, Placebo-Controlled, Phase 3 Studies. The Lancet, 401, 1159-1171.
https://doi.org/10.1016/s0140-6736(23)00061-2
[8] Feagan, B.G., Sands, B.E., Sandborn, W.J., Germinaro, M., Vetter, M., Shao, J., et al. (2023) Guselkumab Plus Golimumab Combination Therapy versus Guselkumab or Golimumab Monotherapy in Patients with Ulcerative Colitis (VEGA): A Randomised, Double-Blind, Controlled, Phase 2, Proof-of-Concept Trial. The Lancet Gastroenterology & Hepatology, 8, 307-320.
https://doi.org/10.1016/s2468-1253(22)00427-7
[9] Zheng, M., Zhai, Y., Yu, Y., Shen, J., Chu, S., Focaccia, E., et al. (2024) TNF Compromises Intestinal Bile-Acid Tolerance Dictating Colitis Progression and Limited Infliximab Response. Cell Metabolism, 36, 2086-2103.e9.
https://doi.org/10.1016/j.cmet.2024.06.008
[10] Collins, K., Kamath, S., Davis, R.H., Costello, S.P., Bryant, R.V., Day, A.S., et al. (2026) Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy. Alimentary Pharmacology & Therapeutics, 64, 729-747.
https://doi.org/10.1111/apt.70826
[11] Gu, Z., Pei, W., Shen, Y., Wang, L., Zhu, J., Zhang, Y., et al. (2021) Akkermansia muciniphila and Its Outer Protein Amuc_1100 Regulates Tryptophan Metabolism in Colitis. Food & Function, 12, 10184-10195.
https://doi.org/10.1039/d1fo02172a
[12] Zhou, S., Wang, M., Li, W., Zhang, Y., Zhao, T., Song, Q., et al. (2024) Comparative Efficacy and Tolerability of Probiotic, Prebiotic, and Synbiotic Formulations for Adult Patients with Mild-Moderate Ulcerative Colitis in an Adjunctive Therapy: A Network Meta-Analysis. Clinical Nutrition, 43, 20-30.
https://doi.org/10.1016/j.clnu.2023.11.010
[13] Dignass, A., Stremmel, W., Horyński, M., Poyda, O., Armerding, P., Fellermann, K., et al. (2024) Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials. Clinical Gastroenterology and Hepatology, 22, 810-820.e7.
https://doi.org/10.1016/j.cgh.2023.09.031
[14] Ahuja, D., Zou, G., Solitano, V., Syal, G., Lee, H.H., Ma, C., et al. (2025) No Impact of Concomitant Medications on Efficacy and Safety of Biologics and Small Molecules for Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 23, 1786-1797.
https://doi.org/10.1016/j.cgh.2024.08.040
[15] Peng, P., Feng, T., Yang, X., Nie, C., Yu, L., Ding, R., et al. (2023) Gastrointestinal Microenvironment Responsive Nanoencapsulation of Probiotics and Drugs for Synergistic Therapy of Intestinal Diseases. ACS Nano, 17, 14718-14730.
https://doi.org/10.1021/acsnano.3c02646
[16] Gao, H., Hu, Z., Zhang, L., Zhao, K., Asai, Y., Li, Y., et al. (2026) Vitamin D3 Facilitates Mucosal Healing and Modulates Macrophage Polarization in DSS-Induced Colitis, Accompanied by Restoration of Epithelial Hippo-Yap Signaling. European Journal of Pharmacology, 1030, Article ID: 179134.
https://doi.org/10.1016/j.ejphar.2026.179134
[17] Zhao, K., Li, J., Asai, Y., Zhang, L., Hu, Z. and Gao, H. (2026) Vitamin D3 Mediates Amelioration of Ulcerative Colitis via the TRPV1-MAPK Signaling Pathway. Frontiers in Immunology, 17, Article 1727932.
https://doi.org/10.3389/fimmu.2026.1727932
[18] Yu, W., Huang, P., Jin, Y., Wu, F., Zhang, C., Jing, L., et al. (2025) Vitamin D Enhances the Therapeutic Effect of TNF-α Antibodies through Lipid Metabolism in Overweight IBD Patients. Cellular and Molecular Life Sciences, 82, Article No. 176.
https://doi.org/10.1007/s00018-025-05626-8
[19] Vallejos, O.P., Bueno, S.M. and Kalergis, A.M. (2025) Probiotics in Inflammatory Bowel Disease: Microbial Modulation and Therapeutic Prospects. Trends in Molecular Medicine, 31, 731-742.
https://doi.org/10.1016/j.molmed.2024.12.005
[20] Wang, K., Zhu, X., Ju, X., Zhou, M. and Shen, G. (2026) From Nutritional Intervention to Immune Modulation: A Multi-Database Bibliometric and Topic Modeling Study of Vitamin D in Inflammatory Bowel Disease. Frontiers in Immunology, 17, Article 1845767.
https://doi.org/10.3389/fimmu.2026.1845767
[21] Liao, G., Zhu, M., Zhang, Y., Zhai, S., Chen, C., Yan, Z., et al. (2026) Mechanism and Active Ingredients of Gancao Qinlian Granules in Ameliorating Ulcerative Colitis: Integrated in Vivo, in Vitro, Network Pharmacology and Untargeted Metabolomics Investigation. Journal of Ethnopharmacology, 373, Article ID: 122263.
https://doi.org/10.1016/j.jep.2026.122263
[22] Yin, Y., Zhao, D., Sun, N., Zhang, Y. and Gao, S. (2026) Physcion Alleviates Ulcerative Colitis by Upregulating SIRT3 to Suppress PANoptosis via Inhibition of the cGAS-STING Pathway. Journal of Ethnopharmacology, 369, Article ID: 121893.
https://doi.org/10.1016/j.jep.2026.121893
[23] Fan, Q., Wang, X., Zhang, H., Chang, Z., Wang, N., Fan, S., et al. (2026) Multi-Dimensional Mechanisms and Druggability Optimization Strategies of Active Ingredients from Traditional Chinese Medicine in the Treatment of Ulcerative Colitis. Pharmaceuticals, 19, Article 977.
https://doi.org/10.3390/ph19070977
[24] Zhang, X., Liu, S., Xin, R., Hu, W., Zhang, Q., Lu, Q., et al. (2025) Reactive Oxygen Species-Responsive Prodrug Nanomicelle-Functionalized Lactobacillus rhamnosus Probiotics for Amplified Therapy of Ulcerative Colitis. Materials Horizons, 12, 5749-5761.
https://doi.org/10.1039/d5mh00114e
[25] Guo, M., Li, B., Li, H., Chen, Y., Yuan, Q., Shui, M., et al. (2025) Colon‐Targeted Natural Polysaccharide‐Berberine Armored Hydrogel for the Treatment of Colitis. Advanced Healthcare Materials, 14, Article ID: 2404908.
https://doi.org/10.1002/adhm.202404908
[26] Cheng, H., Zhang, D., Wu, J., Liu, J., Tan, Y., Feng, W., et al. (2023) Atractylodes macrocephala Koidz. Volatile Oil Relieves Acute Ulcerative Colitis via Regulating Gut Microbiota and Gut Microbiota Metabolism. Frontiers in Immunology, 14, Article 1127785.
https://doi.org/10.3389/fimmu.2023.1127785
[27] Wang, W., Tu, F., Yang, Z., Gu, M., Wang, Y., Gao, Z., et al. (2025) Pectin/Arabinoxylan Dietary Polysaccharide Microcapsule Encapsulated with Clostridium Butyricum for Targeted Delivery in Colitis Treatment. Carbohydrate Polymers, 367, Article ID: 123971.
https://doi.org/10.1016/j.carbpol.2025.123971
[28] Zhao, L., Weng, W., Ni, M., Shen, H., Zhang, S., Chen, Y., et al. (2024) Rubidium Salt Can Effectively Relieve the Symptoms of DSS-Induced Ulcerative Colitis. Biomedicine & Pharmacotherapy, 181, Article ID: 117574.
https://doi.org/10.1016/j.biopha.2024.117574
[29] Yuan, M., Chang, L., Gao, P., Li, J., Lu, X., Hua, M., et al. (2024) Synbiotics Containing Sea Buckthorn Polysaccharides Ameliorate DSS-Induced Colitis in Mice via Regulating Th17/Treg Homeostasis through Intestinal Microbiota and Their Production of BA Metabolites and SCFAs. International Journal of Biological Macromolecules, 276, Article ID: 133794.
https://doi.org/10.1016/j.ijbiomac.2024.133794
[30] Tan, L., Li, Z., Wu, J., Liu, H., Yang, T., Wang, J., et al. (2025) Ginsenoside Rk2 Provides Multidimensional Relief for Ulcerative Colitis by Improving Intestinal Barrier Function, Reshaping Gut Microbiota, and Regulating Th17/Treg Balance. Journal of Agricultural and Food Chemistry, 73, 25340-25357.
https://doi.org/10.1021/acs.jafc.5c04210
[31] Zhang, Y., He, C., Zhao, Y., Jiang, M., Yao, J., Cheng, G., et al. (2025) Yuzhi Zhixue Granules Regulate the JAK/STAT Pathway to Affect T-Cell Differentiation in the Colon of Ulcerative Colitis. Phytomedicine, 147, Article ID: 157198.
https://doi.org/10.1016/j.phymed.2025.157198
[32] Li, P., Chen, G., Zhang, J., Pei, C., Chen, Y., Gong, J., et al. (2022) Live Lactobacillus acidophilus Alleviates Ulcerative Colitis via the SCFAs/Mitophagy/NLRP3 Inflammasome Axis. Food & Function, 13, 2985-2997.
https://doi.org/10.1039/d1fo03360c
[33] Zhao, J., Hu, J. and Ma, X. (2021) Sodium Caprylate Improves Intestinal Mucosal Barrier Function and Antioxidant Capacity by Altering Gut Microbial Metabolism. Food & Function, 12, 9750-9762.
https://doi.org/10.1039/d1fo01975a
[34] Wen, S., He, L., Zhong, Z., Zhao, R., Weng, S., Mi, H., et al. (2021) Stigmasterol Restores the Balance of Treg/Th17 Cells by Activating the Butyrate-PPARγ Axis in Colitis. Frontiers in Immunology, 12, Article 741934.
https://doi.org/10.3389/fimmu.2021.741934
[35] Lim, S.H., Mun, D., Ryu, S., Kang, M., Kang, A., Lee, D.J., et al. (2025) Functional Evaluation of Synbiotic Combination of Kluyveromyces marxianus and Lentilactobacillus kefiri Derived from Milk Kefir Using Multi-Omics Approaches. Current Research in Food Science, 11, Article ID: 101188.
https://doi.org/10.1016/j.crfs.2025.101188
[36] Jin, Y., Niu, Z., Feng, M., Che, H. and Liang, Z. (2025) Inactivated Cells and Metabolites of Saccharomyces boulardii Alleviate Inflammation Damage in Caco-2 Monolayer Cells and Mice with Ulcerative Colitis. Antioxidants, 14, Article 737.
https://doi.org/10.3390/antiox14060737
[37] Liang, L., Liu, L., Zhou, W., Yang, C., Mai, G., Li, H., et al. (2022) Gut Microbiota-Derived Butyrate Regulates Gut Mucus Barrier Repair by Activating the Macrophage/WNT/ERK Signaling Pathway. Clinical Science, 136, 291-307.
https://doi.org/10.1042/cs20210778
[38] Li, W., Zhang, Y., Chen, M., Guo, X. and Ding, Z. (2024) The Antioxidant Strain Lactiplantibacillus plantarum AS21 and Clostridium butyricum Ameliorate DSS-Induced Colitis in Mice by Remodeling the Assembly of Intestinal Microbiota and Improving Gut Functions. Food & Function, 15, 2022-2037.
https://doi.org/10.1039/d3fo05337g
[39] Rubin, D.T., Ananthakrishnan, A.N., Siegel, C.A., Barnes, E.L. and Long, M.D. (2025) ACG Clinical Guideline Update: Ulcerative Colitis in Adults. American Journal of Gastroenterology, 120, 1187-1224.
https://doi.org/10.14309/ajg.0000000000003463
[40] Kumar, S. and Sarkar, B. (2026) From Rodents to Chips: Preclinical Models of Inflammatory Bowel Disease with Emphasis on Host-Microbiome Interactions. American Journal of Physiology-Gastrointestinal and Liver Physiology, 330, G397-G413.
https://doi.org/10.1152/ajpgi.00345.2025
[41] Yang, C. and Merlin, D. (2024) Unveiling Colitis: A Journey through the Dextran Sodium Sulfate-Induced Model. Inflammatory Bowel Diseases, 30, 844-853.
https://doi.org/10.1093/ibd/izad312
[42] Zhang, B., Magnaye, K.M., Stryker, E., Moltzau-Anderson, J., Porsche, C.E., Hertz, S., et al. (2024) Sustained Mucosal Colonization and Fecal Metabolic Dysfunction by Bacteroides Associates with Fecal Microbial Transplant Failure in Ulcerative Colitis Patients. Scientific Reports, 14, Article No. 18558.
https://doi.org/10.1038/s41598-024-62463-8